A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

IRB/UVA Tracking #
20883
Contact
Contact Phone
Phase
I
Primary purpose
Treatment
Cancer PI
Matthew Reilley
Status
OPEN TO ACCRUAL
Ages
Adult